Skip to main content
SpringerLink
Log in

Pharmacokinetics of Anti-Rheumatic Drugs in a Geriatric Patient

  • Chapter
  • First Online:
Rheumatic Disease in Geriatrics

  • 575 Accesses

Abstract

Medical treatment for the elderly can be challenging from a few aspects. First, the diagnosis might be challenging as symptoms and the course of the disease may differ, and as such decisions or choice of the treatment may differ. The medication chosen might have unexpected effects on the elderly patient, in terms of efficacy and safety, as the elderly are seldom included in clinical trials, and as result, there is often sparse evidence on the right dose, safety etc. In this chapter we will focus on the more common drugs used for rheumatic diseases, discuss specific pharmacokinteic and pharmacodynamic changes in the elderly that might influence these drugs safety and efficacy, and suggest preferable choices of drug therapy in this population. 

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278–85.

    Article  CAS  PubMed  Google Scholar 

  2. Hollenberg NK, Rivera A, Meinking T, Martinez G, McCullough M, Passan D, et al. Age, renal perfusion and function in island-dwelling indigenous Kuna Amerinds of Panama. Nephron. 1999;82(2):131–8.

    Article  CAS  PubMed  Google Scholar 

  3. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.

    Article  CAS  PubMed  Google Scholar 

  4. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  CAS  PubMed  Google Scholar 

  6. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601–10.

    Article  CAS  PubMed  Google Scholar 

  7. Klotz U, Klotz Margarete Fischer-Bosch U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.

    Article  CAS  PubMed  Google Scholar 

  8. Krum H, Swergold G, Curtis S, Kaur A, Wang H, Smugar S, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009;27(4):886–93.

    Article  CAS  PubMed  Google Scholar 

  9. Methotrexate Sodium Tablets Prescription Information. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf.

  10. Aletaha D, Funovits J, Pangan A, Baker D, Ko MD, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford). 2009;48:1575–80.

    Article  CAS  Google Scholar 

  11. Bologna C, Viu P, Jorgensen C, Sany J. Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1996;35(5):453–7.

    Article  CAS  PubMed  Google Scholar 

  12. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74.

    Article  CAS  Google Scholar 

  13. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol. 1995;22(2):218–23.

    Google Scholar 

  14. Hirshberg B, Muszkat M, Schlesinger O, Rubinow A. Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J. 2000;76(902):787–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a pro-spective study of 1756 patients. Drug Saf. 2008;31:545–56.

    Article  PubMed  Google Scholar 

  16. Grosser T, Ricciotti E, Fitzgerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci. 2019;38(8):733–48.

    Article  CAS  Google Scholar 

  17. Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs—pharmacological mechanisms and clinical relevance. Thromb Haemost. 2013;109(5):825–33.

    Article  CAS  PubMed  Google Scholar 

  18. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med. 2000;133(1):1.

    Article  CAS  PubMed  Google Scholar 

  19. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes | FDA. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory.

  20. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kalafutova S, Juraskova B, Vlcek J. The impact of combinations of non-steroidal anti-inflammatory drugs and anti-hypertensive agents on blood pressure. Adv Clin Exp Med. 2014;23(6):993–1000.

    Article  PubMed  Google Scholar 

  22. Wang J, Mullins CD, Mamdani M, Rublee DA, Shaya FT. New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study. Ann Pharmacother. 2007;41(6):937–43.

    Article  CAS  PubMed  Google Scholar 

  23. Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247–55.

    Article  PubMed  Google Scholar 

  24. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120:280.e1–7.

    Article  CAS  Google Scholar 

  25. Juhlin T, Björkman S, Höglund P. Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Eur J Heart Fail. 2005;7(6):1049–56.

    Article  CAS  PubMed  Google Scholar 

  26. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000;151(5):488–96.

    Article  CAS  PubMed  Google Scholar 

  27. Kristensen SL, Fosbøl EL, Kamper A-L, Køber L, Hommel K, Lamberts M, et al. Use of nonsteroidal anti-inflammatory drugs prior to chronic renal replacement therapy initiation: a nationwide study. Pharmacoepidemiol Drug Saf. 2012;21(4):428–34.

    Article  PubMed  Google Scholar 

  28. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.

    Article  Google Scholar 

  29. Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5):481–96.

    Article  CAS  PubMed  Google Scholar 

  30. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.

    Article  CAS  PubMed  Google Scholar 

  31. Khanna D, Khanna PP, FitzGerald JD, Singh MK, Bae S, Neogi T et al. American college of rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447–61.

    Article  CAS  Google Scholar 

  32. Colchicine Prescribing Information. 2009.

    Google Scholar 

  33. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226–37.

    Article  CAS  PubMed  Google Scholar 

  34. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–51.

    Article  CAS  PubMed  Google Scholar 

  35. Hopkins AM, Wiese MD, Proudman SM, O’Doherty CE, Upton RN, Foster DJR. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. Br J Clin Pharmacol. 2016;81(1):113–23.

    Article  CAS  PubMed  Google Scholar 

  36. Wiese MD, Schnabl M, O’Doherty C, Spargo LD, Sorich MJ, Cleland LG, et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):1–9.

    Article  CAS  Google Scholar 

  37. Alivernini S, Mazzotta D, Zoli A, Ferraccioli G. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis. Drugs Aging. 2009;26(5):395–402.

    Article  CAS  PubMed  Google Scholar 

  38. Leflunomide Prescription Instructions. 2011.

    Google Scholar 

  39. Baker JF, Sauer BC, Cannon GW, Teng CC, Michaud K, Ibrahim S, et al. Changes in body mass related to the initiation of disease-modifying therapies in rheumatoid arthritis. Arthritis Rheumatol. 2016;68(8):1818–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Betancourt BY, Biehl A, Katz JD, Subedi A. Pharmacotherapy pearls in rheumatology for the care of older adult patients: focus on oral disease-modifying antirheumatic drugs and the newest small molecule inhibitors. Rheum Dis Clin North Am. 2018;44(3):371–91.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Casper Pharma LLC. Allopurinol prescribing information. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016084s044lbl.pdf.

  42. Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr. 2012;12:11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American college of rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–46.

    Article  CAS  Google Scholar 

  44. G VR, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med. 1990;228(1):69–71.

    Article  Google Scholar 

  45. Zimm S, Collins JM, O’Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983;34(6):810–7.

    Article  CAS  PubMed  Google Scholar 

  46. Febuxostat Prescribing Information. 2019.

    Google Scholar 

  47. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894–900.

    Article  PubMed  Google Scholar 

  49. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):16–8.

    Article  CAS  Google Scholar 

  50. Schumacher HR, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Care Res. 2008;59(11):1540–8.

    Article  CAS  Google Scholar 

  51. Becker MA, Schumacher HR, Wortmann RL, Macdonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.

    Article  CAS  PubMed  Google Scholar 

  52. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–10.

    Article  CAS  PubMed  Google Scholar 

  53. Gandhi PK, Gentry WM, Bottorff MB. Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database. Semin Arthritis Rheum. 2013;42(6):562–6.

    Article  CAS  PubMed  Google Scholar 

  54. Su CY, Shen LJ, Hsieh SC, Lin LY, Lin FJ. Comparing cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort study. Mayo Clin Proc. 2019;94(7):1147–57.

    Article  PubMed  Google Scholar 

  55. Chen C, Chen C, Chang CJ, Lin YJ, Wang C-W, Chi C-C, et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians: a population-based cohort study and meta-analysis. Clin Pharmacol Ther. 2019;106(2):391–401.

    Article  CAS  PubMed  Google Scholar 

  56. FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat) FDA Drug Safety Communication. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat.

  57. Cicero AFG, Cosentino ER, Kuwabara M, Degli Esposti D, Borghi C. Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. Intern Emerg Med. 2019;14(6):949–56.

    Article  PubMed  Google Scholar 

  58. Zhang MA, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation. 2018;138(11):1116–26.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Makris UE, Abrams RC, Gurland B, Reid MC. Management of persistent pain in the older patient: A clinical review. JAMA. 2014;312(8):825–36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Ickowicz E. Pharmacological management of persistent pain in older persons. Journal of the American Geriatrics Society. 2009;57:1331–46.

    Article  Google Scholar 

  61. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain— United States, 2016. JAMA. 2016;315(15):1624–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain a spine. Spine (Phila Pa 1976). 2007;32(19):2127–32.

    Article  Google Scholar 

  63. Buckeridge D, Huang A, Hanley J, Kelome A, Reidel K, Verma A, et al. Risk of injury associated with opioid use in older adults. J Am Geriatr Soc. 2010;58(9):1664–70.

    Article  PubMed  Google Scholar 

  64. Miller M, Stürmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc. 2011;59(3):430–8.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Rolita L, Spegman A, Tang X, Cronstein BN. Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults. J Am Geriatr Soc. 2013;61(3):335–40.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Gupta DK, Avram MJ. Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy. Clin Pharmacol Ther. 2012;91(2):339–43.

    Article  CAS  PubMed  Google Scholar 

  67. Malec M, Shega JW. Pain management in the elderly. Med Clin North Am. 2015;99(2):337–50.

    Article  PubMed  Google Scholar 

  68. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497–504.

    Article  CAS  PubMed  Google Scholar 

  69. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82(1):87–96.

    Article  CAS  PubMed  Google Scholar 

  70. Morrison RS, Magaziner J, Gilbert M, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci. 2003;58A(1):76–81.

    Article  Google Scholar 

  71. Tramadex prescription instructions. 2013;1–9.

    Google Scholar 

  72. Targin Prescription Instructions. 2018;(December):1–13.

    Google Scholar 

  73. Codein Prescribing Instructions. 2017.

    Google Scholar 

  74. TaroPharma (per FDA). Product Information: Flo-Pred oral suspension, prednisolone acetate oral suspension. Hawthorne, NY. 2011.

    Google Scholar 

  75. Prednisone Prescription Instructions. 2012;1–16. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020_rayos_toc.cfm.

  76. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.

    Article  CAS  PubMed  Google Scholar 

  77. Tatsuno I, Sugiyama T, Suzuki S, Yoshida T, Tanaka T, Sueishi MSY. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab. 2009;94(5):1671.

    Article  CAS  PubMed  Google Scholar 

  78. Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018 Dec 27;379(26):2547–56.

    Article  PubMed  Google Scholar 

  79. Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: Screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014;6:185–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2017;69(8):1095–110.

    Article  Google Scholar 

  81. Gurwitz JH. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97.

    Article  CAS  PubMed  Google Scholar 

  82. Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105:c54–7.

    Article  CAS  PubMed  Google Scholar 

  83. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry. 2012;169(5):491–7.

    Article  PubMed  Google Scholar 

  84. Tarnowski M, Paradowska-Gorycka A, Dąbrowska-Zamojcin E, Czerewaty M, Słuczanowska-Głąbowska S, Pawlik A. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. Expert Opin Drug Metab Toxicol. 2015;12(1):41–55.

    Article  PubMed  CAS  Google Scholar 

  85. Alzulfidine Label FDA. Sci York. 2009;1–9.

    Google Scholar 

  86. Salazopyrin Label Israel. Pfizer. 2018;1–8.

    Google Scholar 

  87. Wilkieson CA, Madhok R, Hunter JA, et al. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages. Q J Med. 1993;86:501–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HaEmek Medical Center, Afula, Israel

    Lee Hilary Goldstein

  2. Bruce Rappaport School of Medicine, Technion, Haifa, Israel

    Lee Hilary Goldstein

Authors
  1. Lee Hilary Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lee Hilary Goldstein .

Editor information

Editors and Affiliations

  1. Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel

    Gleb Slobodin

  2. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel

    Yehuda Shoenfeld

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Goldstein, L.H. (2020). Pharmacokinetics of Anti-Rheumatic Drugs in a Geriatric Patient. In: Slobodin, G., Shoenfeld, Y. (eds) Rheumatic Disease in Geriatrics . Springer, Cham. https://doi.org/10.1007/978-3-030-44234-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-44234-7_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-44233-0

  • Online ISBN: 978-3-030-44234-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation